I n percutaneous coronary interventions, drug-eluting stents (DESs) have reduced the risk of restenosis and repeat revascularization compared with bare-metal stents. [1] [2] [3] The secondgeneration DESs with thinner stent struts 4,5 have improved safety and efficacy compared with the first-generation DESs 6-8 and has been associated with a reduced risk of late stent thrombosis. 6, 8, 9 The persistence of polymer material on first-and second-generation DESs after completion of drug release has been Background-Coronary drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy.
Sirolimus-Eluting vs Biolimus-Eluting Biodegradable Polymer Stents
suggested as a trigger for a chronic inflammatory response, 10, 11 and third-generation coronary DESs [12] [13] [14] [15] with biodegradable polymers have been designed to overcome concerns over the delayed arterial healing, which might increase the risk of late stent thrombosis and restenosis. Third-generation biolimuseluting stent was designed with a biodegradable polymer. 16 In large randomized trials, the biolimus-eluting stent has shown noninferiority after 1 year to the first-generation sirolimuseluting cypher stent 15 and the second-generation everolimuseluting Xience stent, 14 whereas long-term outcome favored the biolimus-eluting stent. 15 However, in the Scandinavian Organization for Randomized Trials With Clinical Outcome (SORT OUT) V trial, 17 comparing the biolimus-eluting Nobori stent and the sirolimus-eluting Cypher stent, the biolimuseluting stent failed to show noninferiority within 12 months. A cobalt chromium third-generation sirolimus-eluting stent with ultrathin struts, the Orsiro stent, has recently demonstrated noninferiority to the second-generation permanent polymer everolimus-eluting stent at 12 months. 13 The SORT OUT VII trial, a registry-based prospective randomized open-label controlled noninferiority trial with blinded end point adjudication, compared the safety and efficacy outcomes of 2 third-generation DESs with biodegradable polymers: the ultrathin strut sirolimus-eluting Orsiro stent and the biolimus-eluting Nobori stent in a population-based allcomer setting.
Methods

Patients and Study Design
SORT OUT VII is a randomized, multicenter, single-blind, allcomer, 2-arm, blinded end point, noninferiority trial comparing the biodegradable polymer sirolimus-eluting Orsiro stent to the biodegradable polymer biolimus-eluting Nobori stent in treating atherosclerotic coronary artery lesions. Patients were eligible if they were at least 18 years old, had chronic stable coronary artery disease or acute coronary syndromes, and had at least 1 coronary lesion with >50% diameter stenosis, requiring treatment with a DES. If multiple lesions were treated, the allocated study stent had to be used in all lesions. Exclusion criteria were life expectancy of <1 year; an allergy to aspirin, clopidogrel, ticagrelor, prasugrel, sirolimus, or biolimus; participation in another randomized stent trial; or inability to provide written informed consent. The study complied with the Declaration of Helsinki and was approved by the Central Region Denmark ethics committee. All patients provided written informed consent for trial participation before randomization. In 3 patients, the written informed consent was not sufficiently signed and these 3 patients were contacted for a signature, which was required on request from the Ethical Committee of Southern Denmark.
Randomization
Patients were enrolled by the investigators and randomly allocated to treatment groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block randomization by center (permuted blocks of random sizes [2/4/6]) was used to assign patients in a 1:1 ratio to receive the biodegradable polymer sirolimus-eluting stent (Orsiro; Biotronik, Bülach, Switzerland) or the biodegradable polymer biolimus-eluting stent (Nobori; Terumo, Tokyo, Japan). An independent organization computer generated the allocation sequence, stratified by sex and presence of diabetes mellitus. Patients were assigned to treatment through a web-based Trial Partner randomization system. Although operators were not blinded, all individuals analyzing data were masked to treatment assignment.
Study Stent, Procedures, and Antithrombotic Therapy
The sirolimus-eluting Orsiro stent was available in 6 diameters (2.25, 2.50, 2.75, 3.00, 3.50, and 4.00 mm) and 7 lengths (9, 13, 15, 18, 22, 26, and 30 mm) . The thickness of the stent struts is 60 µm for stents with a nominal diameter of ≤3.0 mm and 80 µm for the 2 larger sizes. The stent surface is fully coated with a layer of amorphous hydrogenrich silicon carbide acting as a diffusion barrier (Probio), sealing the bare-metal surface and reducing ion release. The Probio silicon carbide coating consists of silicon carbide, a ceramic material, a chemical compound of the element silicium and the element carbon. The bioabsorbable polymer compound used as a carrier material for the supply and release of sirolimus is a high molecular poly-l-lactic acid. The stent body surface is completely coated by a matrix consisting of the carrier poly-l-lactic acid and the active substance sirolimus. The matrix coating has an abluminal thickness of 7.5 µm and a luminal coating of 3.5 µm. The polymer is completely degraded in 12 to 24 months. The drug load is 1.4 µg/mm, 2,12 and the drug is released during 12 to 14 weeks.
The biolimus-eluting Nobori stent was available in 5 diameters (2.25, 2.50, 2.75, 3.00, and 3.50 mm) and 6 lengths (8, 14, 18, 24, 28, and 33 mm) . The stent strut thickness is 120 µm. The stent platform is composed of stainless steel and a nondegradable parylene coating between the stent and the biodegradable polymer. The biodegradable polylactic acid polymer (PLLA and poly d,l-lactide-co-glycolide) is applied to the abluminal surface and metabolized within 6 to 9 months. 16 The stent elutes biolimus (15.6 μg/mm 2 ), for ≤30 days.
Stents were implanted according to standard techniques. Direct stenting was allowed. Full lesion coverage was attempted by implanting ≥1 stents. DESs not specified by the random allocation scheme and bare-metal stents were prohibited, unless the study stent could not be implanted. In such cases, other stents or balloon angioplasty alone were allowed. Before implantation, patients were treated with acetylsalicylic acid (loading dose of 300 mg) and loaded with clopidogrel 600 mg, ticagrelor 180 mg, or prasugrel 60 mg. Combination of dual-antiplatelet therapy was left to the discretion of the participating center, whereas the duration of dual-antiplatelet therapy was recommended for 12 months. Unfractionated heparin dose (70-100 IU/kg) was administered before the procedure. Glycoprotein IIb/IIIa inhibitors or bivalirudin were used at the operator's discretion.
Outcome Measures
The primary end point target lesion failure is a composite of cardiac death, myocardial infarction (not related to other than index lesion), or
WHAT IS KNOWN
• Second-generation drug-eluting stents with thinner stent struts have improved safety and efficacy compared with the first-generation drug-eluting stents.
• Second-generation drug-eluting stents have been associated with a reduced risk of late stent thrombosis.
• Coronary drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy.
WHAT THE STUDY ADDS
• Stents with biodegradable polymers may not be a class effect.
• Thin-strut sirolimus-eluting Orsiro stent is noninferior to the biolimus-eluting Nobori stent in unselected patients for target lesion failure at 1 year. clinically indicated target lesion revascularization with percutaneous coronary intervention or coronary artery bypass operation within 12 months. Individual components of the primary end point comprise the secondary end points: cardiac death; myocardial infarction; clinically indicated target lesion revascularization; all death (cardiac and noncardiac) and target vessel revascularization; definite, probable, possible, and overall stent thrombosis according to the Academic Research Consortium definition 18 ; and a patient-related composite end point (all death, all myocardial infarctions, or any revascularization).
Definitions
Cardiac Death
Cardiac death is defined as any death due to an evident cardiac cause, any death related to percutaneous coronary intervention, an unwitnessed death, or death from unknown causes.
Myocardial Infarction
Myocardial infarction is the third definition used by the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. 19 Biomarkers were not assessed at the time of the index percutaneous coronary intervention procedure.
Myocardial Infarction Not Related to Other Than Index Lesion
Myocardial infarction not related to other than index lesion is defined as any myocardial infarction that is not clearly attributable to a nontarget vessel.
Stent Thrombosis
Stent thrombosis is a definite, probable, or possible stent thrombosis according to the Academic Research Consortium 18 definition.
Target Vessel Revascularization
Target vessel revascularization is any repeat percutaneous coronary intervention or surgical bypass of any segment within the entire major coronary vessel that was proximal or distal to a target lesion, including upstream and downstream branches, and the target lesion itself.
Target Lesion Revascularization
Target lesion revascularization is defined as repeat revascularization with percutaneous coronary intervention or surgical bypass due to >50% stenosis within the stent or within a 5-mm border proximal or distal to the stent. Target vessel and target lesion revascularization were clinically driven.
Comorbidity
For all patients, we obtained data on all hospital diagnoses from the Danish National Registry of Patients covering all Danish hospitals from 1977 until the implantation date. 20 We then computed Charlson Comorbidity Index score. 21
Clinical Event Detection
Clinically driven event detection was used to avoid study-induced reinterventions. Data on mortality, hospital admission, coronary angiography, repeat percutaneous coronary intervention, and coronary artery bypass surgery were obtained from the following national Danish administrative and healthcare registries: the Civil Registration System 22 ; the Western Denmark Heart Registry 23, 24 ; and the Danish National Registry of Patients, 20 which maintains records on all hospitalizations in Denmark.
The Danish National Health Service provides universal taxsupported health care, guaranteeing residents free access to general practitioners and hospitals. The Danish Civil Registration System has kept electronic records on sex, birthdate, residence, emigration date, and vital status changes since 1968, 22 with daily updates; the 10-digit civil registration number assigned at birth and used in all registries allows accurate record linkage. The Civil Registration System provided vital status data for our study participants and minimized loss to follow-up. The National Registry of Causes of Deaths and the Danish National Registry of Patients provided information on causes of death and diagnoses assigned by the treating physician during hospitalizations (coded according to the International Classification of Diseases, Tenth Revision). 20 An independent event committee, masked to treatment group assignment during the adjudication process, reviewed all end points and source documents to adjudicate causes of death, reasons for hospital admission, and diagnosis of myocardial infarction. Two dedicated percutaneous coronary intervention operators at each participating center reviewed independently cine films for the event committee to classify stent thrombosis, target lesion revascularization, and target vessel revascularization (either with percutaneous coronary intervention or with coronary artery bypass grafting). This methodology has been used in previous SORT OUT III-VI publications. 17, [25] [26] [27] 
Statistical Analysis
The trial was powered for noninferiority of the sirolimus-eluting Orsiro stent to biolimus-eluting Nobori stent with respect to the primary end point at 12 months. An event rate of 6.5% was assumed in each stent group. With a sample size of 1157 patients in each treatment arm, a 2-group large-sample normal approximation test of proportions with a 1-sided 0.050 significance level would have 90% power to detect noninferiority with a predetermined noninferiority margin of 3.0%. The sample size with 1157 in each treatment arm assumed 0% lost-to-follow-up rate given the use of the Civil Registration System. A Farrington-Manning test was used to test for noninferiority. We compared distributions of continuous variables between the study groups using the 2-sample t test (or Cochran test for cases of unequal variance) or the Mann-Whitney U test, depending on whether the data followed a normal distribution. We analyzed distributions of categorical variables using the χ 2 test. In analyses of every end point, follow-up continued until the date of an end point event, death, emigration, or 12 months after stent implantation, whichever came first. We constructed survival curves based on time to events, accounting for the competing risk of death (in cases of death not included in the outcome). Patients who received the biolimus-eluting stent were used as the reference group for overall and subgroup analyses. We calculated rate ratios (RR) for target lesion failure at 12-month follow-up for prespecified patient subgroups (based on baseline demographic and clinical characteristics). The intention-to-treat principle was used in all analyses. Except for the inferiority testing of the primary end point, we regarded a 2-sided P value of <0.05 to indicate statistical significance. We calculated RRs by modified Poisson regression analysis with a sandwich error estimation 28 to assess whether difference detected at baseline had any effect on the result. We did analyses using SAS software (version 9.4). This trial is registered with ClinicalTrials.gov, number NCT01879358.
Results
Between November 2012 and February 2014, 2525 patients were randomly assigned to receive either the biodegradable polymer sirolimus-eluting stent (1261 patients [1590 lesions]) or the biodegradable polymer biolimus-eluting stent (1264patients [1588 lesions]; Figure 1 ). Two patients were lost to follow-up (on days 6 and 81) because of emigration. Complete follow-up data were available for 2523 patients (99.9%) for all type of events. Baseline patient characteristics are summarized in Table 1 and did not differ significantly between the 2 groups except for age, which was higher in the biodegradable polymer sirolimus-eluting stent group (66.1±10.7 years versus 64.8±10.8 years, P=0.003). Lesion and procedure characteristics did not differ significantly between the 2 stent groups except for the reference vessel size, which was slightly larger in the biodegradable polymer sirolimus-eluting stent group (3.2±0.6 mm versus 3.1±0.45 mm; P=0.02; At 1 year, the composite end point target lesion failure occurred in 48 patients (3.8%) in the biodegradable polymer sirolimus-eluting Orsiro group and in 58 patients (4.6%) in the biodegradable biolimus-eluting Nobori group (Figure 2 ; Table 3 ). Noninferiority of the biodegradable polymer sirolimus-eluting Orsiro stent was documented with an absolute risk difference −0.78% and the upper limit of 1-sided 95% confidence interval (CI) at 0.61% (P<0.0001 in 1-sided noninferiority test).
Rates of death, cardiac death, myocardial infarction, and clinically driven target lesion revascularization at 1 year did not differ significantly between the 2 stent groups (Figure 2 ; Table 3 ). Adjusting for age and reference vessel diameter did not change the risk ratio significantly except for the noncardiac death rate, which no longer differed significantly between the 2 groups (Orsiro stent group 22 [ Figure 2 ; Table 2 ). This reduced rate of definite stent thrombosis in the biodegradable polymer sirolimus-eluting stent was attributable to a lower risk of early definite stent thrombosis (≤30 days): (n=2 [0.2%] versus n=10 [0.8%]; RR, 0.20; 95% CI, 0.04-0.91; P=0.038). Among patients with definite stent thrombosis within the first year, 20 of 20 patients (100%) were in dual-antiplatelet therapy with aspirin and clopidogrel/ticagrelor/prasugrel. Overall definite/probable stent thrombosis rates did not differ significantly between the 2 groups (11 [0.9%] versus 20 [1.6%]; RR, 0.55; 95% CI, 0.26-1.15; P=0.11; Figure 2 ; Table 3 ).
Findings for the primary end point target lesion failure were consistent across prespecified stratified analyses (Figure 3 ). Because thin-strut biodegradable polymer sirolimus-eluting stent has 2 different platforms of 60 and 80 µm in thickness, target lesion failure and stent thrombosis were calculated for both different platforms of the biodegradable polymer sirolimus-eluting stent and compared with the 
Discussion
In the SORT OUT VII, the biodegradable polymer ultrathin strut sirolimus-eluting Orsiro stent was noninferior to the biodegradable polymers biolimus-eluting Nobori stent for target lesion failure at 12 months. Rates of cardiac mortality, myocardial infarction, and target lesion revascularization did not differ significantly between the 2 groups, although definite stent thrombosis was lower in the sirolimus-eluting Orsiro stent group.
The SORT OUT VII demonstrated excellent results with low target lesion failure rates and low stent failure rates during implantation in both the stent groups in an all-comer population. This study compared 2 different third-generation 15 the newer sirolimus-eluting Orsiro stent have a silicon carbide coating, thinner stent struts (60-80 µm compared with the 120 µm for the biolimus-eluting stent), slower drug release (12 weeks versus ≈4 weeks), and polymer degradation is taking place after 12 to 24 months compared with 6 to 9 months for the biolimus-eluting stent. The ultrathin strut sirolimus-eluting stent has circumferential polymer coating compared with an abluminal location for the biolimus-eluting stent. Slower polymer degradation or thinner stent struts may reduce the inflammatory response and the risk of early stent thrombosis. DESs have improved and been developed with flexible designs 29, 30 and progressively thinner strut profiles. 13, 31, 32 Thin stent struts have been associated with less wall shear and thrombogenicity, 33 which may be an explanation for the lower stent thrombosis rate in the SORT OUT VII despite that thinner stent struts may be more prone to longitudinal compression 34 and to an increased risk of tissue prolapse intensifying thrombogenicity. 35 In head-to-head randomized trials, the biodegradable polymer stents have shown noninferiority to the durable flouropolymer everolimus-eluting stent 13, 14 and the first-generation sirolimus-eluting stent 15 within the first year after stent implantation, whereas the biolimus-eluting Nobori stent failed to show noninferiority within 1 year in the SORT OUT V trial. 17 In A 13 trial, the biodegradable polymer sirolimus-eluting Orsiro was noninferior to the durable flouropolymer everolimus-eluting stent for target lesion failure at 1 year and no significant differences were noted in stent thrombosis.
The target lesion failure rate for the sirolimus-eluting Orsiro stent was lower in the SORT OUT VII compared with the BIOSCIENCE 13 trial. This difference can be explained partly by the procedure-related myocardial infarction, which was not part of the primary end point in the SORT OUT VII trial, and by the slightly higher clinically indicated target lesion revascularization rate in the BIOSCIENCE trial. The SORT OUT VII trial, such as the previous SORT OUT trials, 7, 17, 25, 27 relied on registry-based event detection without study-related angiographic or clinical follow-up. Patient care complied with standard clinical practice (hospital outpatient visit after 1-3 months). We think that this approach to detection of events, combined with the randomized all-comer trial design, allowed us to assess the efficacy of different percutaneous coronary interventions in a context reflecting everyday clinical practice during the study period. Although the Danish healthcare databases capture events of sufficient severity for patients to seek medical attention, these records might underestimate event rates compared with follow-up by dedicated trial staff. However, this situation should not bias differences detected between the treatment groups, and the negligible loss to follow-up probably compensated for this potential limitation. The design of the study assumed a higher event rate, and the impact of a lower than anticipated event rate makes it less likely that one would reject the hypothesis of noninferiority. Our primary end point might be limited by the short follow-up period. Consequently, the safety and performance of the stents included in SORT OUT VII will be assessed yearly ≤5 years.
Conclusions
In conclusion, the SORT OUT VII trial showed the biodegradable polymer sirolimus-eluting Orsiro stent was noninferior to the biodegradable polymer biolimus-eluting Nobori stent in unselected patients for target lesion failure at 1 year. The sirolimus-eluting Orsiro stent was associated with a reduced risk of definite stent thrombosis.
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